Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Payables (2016 - 2026)

Standard Biotools has reported Payables over the past 16 years, most recently at $5.4 million for Q4 2025.

  • Quarterly Payables rose 7.09% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, up 7.09% year-over-year, with the annual reading at $5.4 million for FY2025, 7.09% up from the prior year.
  • Payables was $5.4 million for Q4 2025 at Standard Biotools, down from $6.6 million in the prior quarter.
  • Over five years, Payables peaked at $13.1 million in Q1 2024 and troughed at $5.0 million in Q4 2024.
  • The 5-year median for Payables is $9.3 million (2022), against an average of $9.3 million.
  • Year-over-year, Payables plummeted 51.19% in 2023 and then skyrocketed 115.11% in 2024.
  • A 5-year view of Payables shows it stood at $10.6 million in 2021, then dropped by 25.35% to $7.9 million in 2022, then increased by 16.7% to $9.2 million in 2023, then tumbled by 45.33% to $5.0 million in 2024, then grew by 7.09% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Payables are $5.4 million (Q4 2025), $6.6 million (Q3 2025), and $7.3 million (Q2 2025).